| Titre | | nb de chargement | |
|---|
| Transgene Announces Upcoming Investor Meetings | | 1311 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 1288 | |
| All of Transgene's preclinical and clinical assets progressed in line with expectations in Q1 2022 | | 1480 | |
| Progression de tous les produits précliniques et cliniques de Transgene au premier trimestre 2022 | | 2438 | |
| Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination | | 1208 | |
| Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination | | 1208 | |
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 1230 | |
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 1230 | |
| Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050 | | 5884 | |
| Transgene présente de nouvelles données préliminaires de Phase I confirmant le potentiel de TG4050 au congrès de l'AACR 2022 | | 4246 | |
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 3561 | |
| Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF | | 3561 | |
| Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF | | 3561 | |
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 3561 | |
| Availability of Transgene's 2021 Universal Registration Document | | 4495 | |
| Mise à disposition du document d'enregistrement universel 2021 de Transgene | | 4143 | |
| Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022 | | 4323 | |
| Mise à disposition des documents préparatoires à l'Assemblée générale du 25 mai 2022 | | 4059 | |
| Transgene's Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman | | 6499 | |
| Le conseil d'administration de Transgene renforce sa gouvernance et propose la nomination du Dr Alessandro Riva en qualité de Président Indépendant | | 4090 | |
| Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022 | | 17404 | |
| Transgene confirme le potentiel de ses deux plateformes innovantes et attend des résultats cliniques significatifs en 2022 | | 5291 | |
| Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022 | | 8752 | |
| Transgene et BioInvent présenteront un poster à l'AACR 2022 sur BT-001, un virus oncolytique innovant | | 5242 | |
| Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022 | | 7011 | |
| Transgene présentera des nouvelles données préliminaires positives des Phases I avec TG4050 à l'AACR 2022 | | 5467 | |
| BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment | | 4727 | |
| BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment | | 4727 | |
| Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject "cold" tumors | | 4727 | |
| Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject "cold" tumors | | 4727 | |
| Éthique et conformité | | 4727 | |
| Corporate governance | | 4727 | |
| Ethics & compliance | | 4727 | |
| Transgene appoints Steven Bloom as Chief Business Officer | | 9603 | |
| Transgene annonce la nomination de Steven Bloom au poste de Directeur du Business Development | | 5269 | |
| Ethics and compliance | | 4727 | |
| Éthique & conformité | | 4727 | |
| Custom Styles | | 4729 | |
| Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject 'cold' tumors | | 4733 | |
| Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject cold tumors | | 4733 | |
| Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade | | 7237 | |
| Transgene et BioInvent publient dans le JITC des données de preuve de concept préclinique du virus oncolytique BT-001 | | 6909 | |
| | 4733 | |
| Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors | | 13533 | |
| Transgene et PersonGen annoncent une collaboration pour l'évaluation d'une nouvelle combinaison thérapeutique contre les tumeurs solides | | 11307 | |
| Transgene announces Financial Calendar for 2022 | | 5490 | |
| Transgene présente son calendrier de communication financière pour 2022 | | 5852 | |
| Biomed Event - Paris | | 7945 | |
| Biomed Event - Paris | | 7945 | |
| Biotech Showcase Investor Conference Digital- January 17 to 19, 2022 | | 7945 | |
| Biotech Showcase Investor Conference Virtuel - 17 au 19 janvier 2022 | | 7945 | |
| Biotech Showcase Investor Conference, in conjunction with the J.P. Morgan Healthcare conference - Digital - January 10 to 12, 2022 | | 7945 | |
| Biotech Showcase Investor Conference, en parallèle de la conférence annuelle J. P. Morgan - Virtu - 10 au 12 janvier 2022 | | 7945 | |
| 25th ODDO BHF Digital Forum - Digital - January 6, 7, 10 and 11, 2022 | | 7945 | |
| 11ème édition du LifeSci Advisors Corporate Access Event - Virtuel - 5 au 7 janvier 2022 | | 7945 | |
| 11th Annual LifeSci Advisors Corporate Access Event - Digital - January 5 to 7, 2022 | | 7945 | |
| ODDO BHF Digital Forum - Virtuel - 6, 7, 10 et 11 janvier 2022 | | 7945 | |
| Transgene announces investor Meeting for January 2022 | | 8546 | |
| Transgene annonce ses rencontres avec les investisseurs en janvier 2022 | | 10002 | |
| License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Invir.IO Platform | | 7945 | |
| Levée dOption de Licence par AstraZeneca pour un Virus Oncolytique issu de la Plateforme Invir.IO | | 7945 | |
| Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgenes Invir.IO Platform | | 31869 | |
| Transgene annonce une levée doption de licence par AstraZeneca pour un virus oncolytique issu de sa plateforme Invir.IO | | 11353 | |
| TG4050, First positive clinical data from Phase I clinical trials | | 7945 | |
| TG4050, Premiers résultats positifs des essais de Phase I (en français) | | 7945 | |
| Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine | | 19620 | |
| Transgene et NEC annoncent des premiers résultats positifs des essais de Phase I de TG4050, un vaccin thérapeutique individualisé innovant contre le cancer | | 10085 | |
| annonceHome | | 7945 | |
| annonceHomeUS | | 7945 | |
| TG4050 | | 7945 | |
| Icon | | 7945 | |
| TG4050 | | 7945 | |
| annonce substitut | | 7945 | |
| annonce | | 7945 | |
| Careers | | 7945 | |
| Annual General Meeting | | 7945 | |
| événements et presentations | | 7945 | |
| Analysts | | 7945 | |
| General | | 7945 | |
| Key figures | | 7945 | |
| Financial reports | | 7945 | |
| Information boursière | | 7945 | |
| Financial information | | 7945 | |
| Regulated information | | 7945 | |
| Publications | | 7945 | |
| RH(en) | | 7945 | |
| Icon | | 7945 | |
| Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021 | | 8377 | |
| Transgene reports business update and Q3 2021 financial position | | 7945 | |
| Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021 | | 8144 | |
| Transgene et BioInvent présentent des données précliniques soulignant la forte activité antitumorale du virus oncolytique BT-001 au SITC 2021 | | 8567 | |
| Transgene publie sa situation financière et fait un point sur son activité au troisième trimestre 2021 | | 8540 | |
| Transgene et BioInvent présenteront des données précliniques sur le virus oncolytique BT-001 au SITC 2021 | | 8188 | |
| annonce substitut | | 7945 | |
| annonce | | 7945 | |
| annonce | | 7945 | |
| TG4050 | | 7945 | |
| Nous rejoindre | | 7945 | |
| esmo | | 7945 | |
| esmo2021 | | 7945 | |
| bg3 | | 7945 | |
| bg2 | | 7945 | |
| bg1 | | 7945 | |
| Statistiques | | 7945 | |
| RH | | 7945 | |
| produits : BT-001 | | 7945 | |
| produits : TG6002 | | 7945 | |
| produits : TG4001 | | 7945 | |
| produits : TG4050 | | 7945 | |
| Publications | | 7945 | |
| techno invirio | | 7945 | |
| techno myvac | | 7945 | |
| techno Oncolytic viruses | | 7945 | |
| techno Therapeutic Vaccines | | 7945 | |
| FAQ | | 7945 | |
| | 7945 | |
| produits : 5 OVs teaser | | 7945 | |
| produits : OVs teaser | | 7945 | |
| produits : BT-001 teaser | | 7945 | |
| produits : TG6002 teaser | | 7945 | |
| produits : TG4001 teaser | | 7945 | |
| produits : TG4050 teaser | | 7945 | |
| pipeline | | 7945 | |
| CORPORATE GOVERNANCE | | 7945 | |
| Dr. Laurence ZITVOGEL | | 7945 | |
| Sandrine Flory TSGH | | 7945 | |
| Maya SAID | | 7945 | |
| Alain MÉRIEUX | | 7945 | |
| Marie LANDEL | | 7945 | |
| Benoît HABERT | | 7945 | |
| Dr. Jean-Pierre BIZZARI | | 7945 | |
| Antoine BÉRET | | 7945 | |
| Jean-Luc BÉLINGARD | | 7945 | |
| conseil | | 7945 | |
| Philippe ARCHINARD | | 7945 | |
| Gaëlle STADTLER | | 7945 | |
| John FELITTI | | 7945 | |
| Steven Bloom | | 7945 | |
| Jean-Philippe Del | | 7945 | |
| Maud BRANDELY | | 7945 | |
| Christophe ANCEL | | 7945 | |
| Eric QUÉMÉNEUR | | 7945 | |
| Hedi Ben Brahim | | 7945 | |
| Management committee | | 7945 | |
| Home news plugin | | 7945 | |
| innovation box | | 7945 | |
| TG4001 box | | 7945 | |
| myvac-box | | 7945 | |
| invirio-box | | 7945 | |
| videos | | 7945 | |
